The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call

West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response remained muted. Management attributed the outperformance to robust growth in its Proprietary Products, particularly high-value product (HVP) components for biologics and biosimilars. CEO Eric Green highlighted, “Our performance was driven by the execution of our strategy and continued operational excellence initiatives,” pointing to the company’s strong recovery following a cyber incident and the expansion of advanced containment solutions as key factors supporting the quarter.

Is now the time to buy WST? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call

• Michael Ryskin (Bank of America): asked about the sustainability of non-GLP-1 HVP component growth. CEO Eric Green explained that strong biologics pipelines, regulatory-driven upgrades, and operational resilience underpin the momentum, calling it a “multiyear opportunity.”
• Paul Knight (KeyBanc): inquired about capacity utilization at major facilities. Green detailed productivity improvements at Eschweiler, nearing target utilization at Grand Rapids, and ongoing ramp-up at Dublin, with full capacity expected to be leveraged in coming quarters.
• Patrick Donnelly (Citi): questioned margin expansion drivers for the second half. CFO Robert McMahon pointed to pricing momentum, product mix shift, and operational leverage as key factors, and suggested further upside is possible with ongoing initiatives.
• Daniel Markowitz (Jefferies): asked whether guidance assumes a slowdown in GLP-1 component demand. McMahon clarified the outlook reflects prudent forecasting, not a market slowdown, and that international generic launches will be a bigger driver in future years.
• Kallum Titchmarsh (Morgan Stanley): sought specifics on Asia Pacific growth. Green highlighted China and India as primary contributors, particularly in GLP-1 biosimilars, with South Korea showing increasing innovation and contract manufacturing activity.

Catalysts in Upcoming Quarters

In the coming quarters, StockStory’s analysts will closely monitor (1) the pace of biologic and biosimilar drug approvals and West’s win rates in complex containment solutions, (2) execution on regulatory-driven HVP upgrades, especially as Annex 1 adoption spreads beyond Europe, and (3) the ramp-up of GLP-1 component sales in emerging markets and for new indications. Progress in operational execution and the performance of the West Vantage segment will also be important metrics for tracking the company’s strategic progress.

West Pharmaceutical Services currently trades at $336.68, down from $358.41 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.